Diagnosis and management of neuroendocrine prostate cancer
The Prostate · 2024-04 · 84 (5) · 426-440
DOI: 10.1002/pros.24664 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Prostate, online erschienen am 03.01.2024. Verfasst von Ivan de Kouchkovsky und 4 weiteren Autor:innen. Beteiligte Einrichtung: Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Adenocarcinoma, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 100 Literaturangaben. Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Abstract (Originalsprache)
Background
Although most patients with prostate cancer (PC) respond to initial androgen deprivation therapy (ADT), castration‐resistant disease invariably develops. Progression to treatment‐emergent neuroendocrine PC (t‐NEPC) represents a unique mechanism of resistance to androgen receptor (AR)‐targeted therapy in which lineage plasticity and neuroendocrine differentiation induce a phenotypic switch from an AR‐driven adenocarcinoma to an AR‐independent NEPC. t‐NEPC is characterized by an aggressive clinical course, increased resistance to AR‐targeted therapies, and a poor overall prognosis.
Methods
This review provides an overview of our current knowledge of NEPC, with a focus on the unmet needs, diagnosis, and clinical management of t‐NEPC.
Results
Evidence extrapolated from the literature on small cell lung cancer or data from metastatic castration‐resistant PC (mCRPC) cohorts enriched for t‐NEPC suggests an increased sensitivity to platinum‐based chemotherapy. However, optimal strategies for managing t‐NEPC have not been established, and prospective clinical trial data are limited. Intertumoral heterogeneity within a given patient, as well as the lack of robust molecular or clinical biomarkers for early detection, often lead to delays in diagnosis and prolonged treatment with suboptimal strategies (i.e., conventional chemohormonal therapies for mCRPC), which may further contribute to poor outcomes.
Conclusions
Recent advances in genomic and molecular classification of NEPC and the development of novel biomarkers may facilitate an early diagnosis, help to identify promising therapeutic targets, and improve the selection of patients most likely to benefit from NEPC‐targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
- Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, California, USA.
- Department of Pathology, University of California San Francisco, San Francisco, California, USA.
- Merck & Co., Inc., Rahway, New Jersey, USA.
ORCID-Profile: Ivan de Kouchkovsky
Förderung
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Zitieren
APA
de Kouchkovsky, I., Chan, E., Schloss, C., Poehlein, C., & Aggarwal, R. (2024). Diagnosis and management of neuroendocrine prostate cancer. The Prostate, 84(5), 426-440. https://doi.org/10.1002/pros.24664
Vancouver
de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R. Diagnosis and management of neuroendocrine prostate cancer. The Prostate. 2024;84(5):426-440. doi:10.1002/pros.24664
BibTeX
@article{deKouchkovsky2024,
author = {de Kouchkovsky, Ivan and Chan, Emily and Schloss, Charles and Poehlein, Christian and Aggarwal, Rahul},
title = {Diagnosis and management of neuroendocrine prostate cancer},
journal = {The Prostate},
year = {2024},
volume = {84},
number = {5},
pages = {426--440},
doi = {10.1002/pros.24664}
}
EUVIMED